What is Cargene Therapeutics?
Cargene Therapeutics is a Singapore-based biopharmaceutical company dedicated to developing novel therapies for cardiovascular, fibrotic, and pulmonary diseases. The company's focus on these complex conditions positions it within a critical area of medical research and development. Its strategic location in Singapore provides access to a vibrant biotech ecosystem and potential for global expansion.
How much funding has Cargene Therapeutics raised?
Cargene Therapeutics has raised a total of $19.2M across 1 funding round:
Other Financing Round
$19.2M
Other Financing Round (2021): $19.2M with participation from Legendstar Capital, BioTrack Capital, and Hyfinity Investments
Key Investors in Cargene Therapeutics
Legendstar Capital
Legendstar Capital is an investor participating in the funding round, likely focusing on strategic growth opportunities within the life sciences sector.
BioTrack Capital
Founded in 2017, BioTrack Capital is a dedicated healthcare venture capital firm focused on building and incubating innovative life science companies in China. They seek to discover innovative biotech companies, medtech companies, and business models led by outstanding entrepreneurs.
Hyfinity Investments
Hyfinity Investments is an investor participating in the funding round, likely contributing capital to support Cargene Therapeutics' strategic objectives.
What's next for Cargene Therapeutics?
The substantial enterprise-level funding and recent strategic investment suggest Cargene Therapeutics is poised for an accelerated growth phase. This capital infusion is likely to fuel further research and development, clinical trial progression, and potential expansion of its therapeutic pipeline. The company's trajectory indicates a move towards scaling its operations and advancing its lead candidates towards commercialization, aiming to make a significant impact on patients suffering from cardiovascular, fibrotic, and pulmonary ailments.
See full Cargene Therapeutics company page
